Comparing Remimazolam and Midazolam for Anesthesia Induction in Patients 65 and Older Undergoing Elective Non-Cardiac Surgery

What this Trial Is About

Researchers are evaluating two benzodiazepine sedatives, remimazolam and midazolam, for general anesthesia induction in elderly patients aged 65 years and older undergoing elective non-cardiac surgery. This observational cohort study aims to compare their effectiveness and safety, focusing on anesthesia-related complications common in older adults, such as low blood pressure during surgery, delayed awakening, and postoperative delirium. The study observes routine clinical care without altering treatment choices. Participants receive either remimazolam or midazolam as the sedative during anesthesia induction, with the final dose and sequence determined by the attending anesthesiologist. The study groups are defined based on the sedative used, and all patients receive standard monitoring including ECG, oxygen levels, blood pressure, and anesthetic depth. Data collected include patient demographics, medical and medication history, laboratory results, and detailed intraoperative information like surgery type, duration, blood loss, and medication doses. During the study, researchers collect information on blood pressure changes during surgery, use of drugs to support blood pressure, time to remove breathing tubes, quality of recovery after 24 hours, anxiety levels, major organ complications, anesthesia-related adverse events, and length of stay in the recovery unit. This data helps assess the safety and recovery profiles of the two sedatives. Participation lasts through the surgery and hospital stay, with follow-up until discharge, averaging about seven days.

Remimazolam Versus Midazolam for General Anesthesia Induction in Elderly Patients Undergoing Non-Cardiac Surgery